Pomerantz Law Firm Launches Investigation on enGene Therapeutics Investors Amid Concerns of Securities Fraud

Investor Alert: Pomerantz Law Firm Investigates enGene Therapeutics

Pomerantz LLP, a renowned law firm specializing in corporate and securities litigation, has initiated an investigation on behalf of investors in enGene Therapeutics Inc. (NASDAQ: ENGN). The firm is examining claims against the company and some of its executives regarding potential engagement in securities fraud and other illicit business practices. This inquiry follows troubling announcements from enGene regarding their ongoing clinical trials, raising significant concerns about the integrity of their financial disclosures and operational transparency.

On May 7, 2026, enGene reported interim results from its pivotal Phase 2 LEGEND trial concerning the efficacy of detalimogene voraplasmid for patients suffering from high-risk, BCG-unresponsive non-muscle invasive bladder cancer. The company revealed a starkly disappointing outcome, indicating that only 25% of patients exhibited a 12-month duration of response, which fell considerably short of expectations. Such a revelation prompted a dramatic decline in enGene’s stock price, plummeting by $7.13 per share—equating to a staggering 80.56% drop—closing at just $1.72 a share on the same day.

The implications of this investigation are significant as Pomerantz LLP is well-known for defending the rights of shareholders and victims of corporate misconduct. With a legacy spanning over 85 years, the firm has achieved numerous multimillion-dollar settlements and continues to uphold the principles established by its founder, Abraham L. Pomerantz, a respected figure in class action litigation. The firm’s scope extends across major cities, operating out of New York, Chicago, Los Angeles, and several international locations, showcasing their broad commitment to justice for investors.

For affected investors in enGene Therapeutics, it is essential to remain vigilant. If you have experienced losses in your investment due to the recent downturn and believe you may be impacted by this matter, Pomerantz encourages you to reach out to their dedicated representative, Danielle Peyton, via email or phone. Investors should act promptly, as involvement in class action suits often requires timely decisions regarding participation.

The gravity of the situation surrounding enGene Therapeutics’s performance cannot be understated. Investors must consider the ramifications that such clinical trial results and subsequent stock price manipulation allegations could have on their investments. Legal analysts are keeping a close eye on how this investigation unfolds and what it could potentially mean for the future of enGene and its shareholders.

As we await more information from Pomerantz LLP and the responses from enGene Therapeutics, investors are advised to stay informed and evaluate their options regarding this developing situation. This event is not just a wake-up call but perhaps a pivotal moment for many holding shares in the biopharmaceutical sector, reinforcing the need for transparency and accountability in corporate governance. As this story develops, it promises to reveal more about the challenges and responsibilities inherent in the biotech investment landscape.